Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Total Debt

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Total Debt

ANEB · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
21.67M
-12.3%-2.1%N/A
1.07M
N/A84.6%N/A
39.58M
-4.7%-2.9%N/A
12.03M
-7.3%54.2%2.4%
1.59M
-46.4%-11.0%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
1.24M
-8.3%11.5%N/A
61.65M
-45.2%-27.3%N/A
825.00K
-74.8%9.1%N/A
14.81M
2.4%66.4%N/A
736.00K
-45.7%-35.4%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72